NCT03793361 2026-03-18
EREMISS
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
24 trialsNCT01900743 2026-03-13
REGO-SARC
Centre Oscar Lambret
Phase 2 Completed
NCT02310477 2026-03-13
REBECCA
Centre Oscar Lambret
Completed
NCT02386397 2026-03-12
BREGO
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT06071052 2026-03-05
DREAM
First Affiliated Hospital, Sun Yat-Sen University
Phase 2 Completed
NCT06137170 2026-03-02
RegoSeq
Bayer
Completed
NCT03828799 2026-02-27
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT03712943 2026-02-09
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04362839 2026-01-28
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1 Completed
NCT03994601 2026-01-20
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Bristol-Myers Squibb
Phase 1/2 Completed
NCT06095375 2026-01-09
REGOMA-2
Istituto Oncologico Veneto IRCCS
Phase 1 Completed
NCT03042689 2026-01-08
Study of Regorafenib in Patients With Advanced Myeloid Malignancies
Massachusetts General Hospital
Phase 1 Completed
NCT03377361 2025-12-03
CheckMate 9N9
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05839951 2025-11-12
STAR-T
Bayer
Completed
NCT04660812 2025-10-20
ARC-9
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT05064059 2025-09-17
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02098538 2025-09-10
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04874207 2025-08-08
RePERSO
Rennes University Hospital
Phase 4 Completed
NCT02368886 2025-06-18
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT04051606 2025-06-05
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 2 Completed
NCT04696055 2025-05-13
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
Phase 2 Completed
NCT04704154 2025-04-18
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Bayer
Phase 2 Completed
NCT02934529 2025-04-16
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Phase 3 Completed